September 26, 2023

Dear Rett Community,

We are writing to share a series of updates that Taysha provided in a press release earlier today. Please find a summary of the updates below, as well as a list of answers to some questions you may have.

- The second adult patient was dosed with the investigational gene therapy, TSHA-102, in the REVEAL Adult Study
- Available clinical data from the first two adult patients dosed with TSHA-102 will be shared in an upcoming quarterly earnings call for investors in mid-November, following review of the data by the Independent Data Monitoring Committee (IDMC)
- The third adult patient is expected to be dosed with TSHA-102 in the fourth quarter of 2023, which would potentially complete enrollment of the low-dose cohort in the REVEAL Adult Study
- Dosing of the first pediatric Rett syndrome patient with TSHA-102 in the REVEAL Pediatric Study in the United States (U.S.) is expected to take place in the first quarter of 2024

**What is the REVEAL Adult Study?**
- The REVEAL Adult Study is a Phase 1/2 open-label dose-escalation clinical trial designed to evaluate the potential safety, tolerability, and preliminary efficacy of a single administration of the investigational gene therapy, TSHA-102, in adult females 18 years and older with Rett syndrome
- The study is designed to evaluate two different dose levels to determine the optimal amount (highest tolerable dose) of TSHA-102
  - To date, the two dosed participants have been given the first dose level being assessed in the clinical trial
  - The third participant will also receive the first dose level
- The study is currently being conducted at CHU Sainte-Justine, the Université de Montréal mother and Child University Hospital Centre in Montreal, Canada

**What is the REVEAL Pediatric Study?**
- As announced in August 2023, the U.S. Food and Drug Administration (FDA) cleared an investigational new drug (IND) application for Taysha’s investigational gene therapy, TSHA-102, in female children with Rett syndrome
- The REVEAL Pediatric Study will study TSHA-102 in female children 5-8 years old, with plans to expand to female children 3-8 years old in future parts of the study
- The REVEAL Pediatric Study is not yet open for enrollment
  - As soon as enrollment begins, Taysha will share a letter to the community with details about the clinical trial, including inclusion and exclusion criteria, study site locations, number of participants and other details about the protocol
  - Details will also be available on [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

**What are Taysha’s plans for a clinical trial for females with Rett syndrome in the United Kingdom (UK)?**
- Taysha submitted a clinical trial application to the UK Medicines and Healthcare products Regulatory Agency (MHRA) to study TSHA-102 in female children with Rett syndrome and expects to receive MHRA feedback in the second half of 2023
If you would like to connect with someone from the Taysha Patient Affairs team, please contact patientaffairs@tayshagtx.com. If your healthcare provider would like to connect with a member of our Taysha Medical Affairs team, please contact medinfo@tayshagtx.com.

We would like to thank the entire Rett community and the Rett patient advocacy groups for your continued partnership. We would also like to acknowledge the individuals and families participating in the trial for contributing to this important research to better understand the potential of gene therapy for Rett syndrome.

We look forward to sharing more information as it is publicly available.

Sincerely,
The Taysha Patient Affairs Team